AXSM vs. HCM, INSM, PBH, CRNX, RARE, BHVN, SMMT, PRGO, ALKS, and IDYA
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include HUTCHMED (HCM), Insmed (INSM), Prestige Consumer Healthcare (PBH), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Summit Therapeutics (SMMT), Perrigo (PRGO), Alkermes (ALKS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
Axsome Therapeutics (NASDAQ:AXSM) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Axsome Therapeutics currently has a consensus price target of $121.92, suggesting a potential upside of 59.28%. HUTCHMED has a consensus price target of $29.70, suggesting a potential upside of 47.25%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than HUTCHMED.
HUTCHMED has higher revenue and earnings than Axsome Therapeutics.
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 24.5% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
HUTCHMED has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -118.07%. HUTCHMED's return on equity of 0.00% beat Axsome Therapeutics' return on equity.
Axsome Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Axsome Therapeutics received 110 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 68.67% of users gave Axsome Therapeutics an outperform vote while only 66.60% of users gave HUTCHMED an outperform vote.
In the previous week, HUTCHMED had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 8 mentions for HUTCHMED and 6 mentions for Axsome Therapeutics. HUTCHMED's average media sentiment score of 0.58 beat Axsome Therapeutics' score of -0.52 indicating that HUTCHMED is being referred to more favorably in the news media.
Summary
Axsome Therapeutics beats HUTCHMED on 9 of the 16 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
